VUB spin-off Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a €80M Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads.
The company's lead product candidate, CAM-H2, is currently in a Phase I/II study for the treatment of HER2-positive metastatic breast and gastric cancer. The proceeds of this financing round will fund the development and expansion of Precirix’s pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study, and plans to bring additional novel radiopharmaceuticals to the clinic.
Article in De Tijd
